Seeking Alpha

Things could get dicey for Intuitive Surgical over the next few days, as CNBC rolls out the "The...

Things could get dicey for Intuitive Surgical over the next few days, as CNBC rolls out the "The da Vinci Debate," a critical expose on ISRG's high-tech da Vinci robot. The piece comes at a difficult time for the company, who earlier today acknowleged in a 10-Q filing that it's currently the defendent in approximately 26 individual product liability lawsuits by plaintiffs who allege that they sustained a variety of personal injuries and, in some cases, death as a result of the robotic surgery.
From other sites
Comments (13)
  • farcry
    , contributor
    Comments (25) | Send Message
     
    ISRG stock is likely to be volatile until at least one court case absolves the company of blame for injuries associated with use of the Da Vinci system. In the meantime, the stock likely will rise and fall with what the plaintiffs' and respondent's testify.
    19 Apr 2013, 09:32 PM Reply Like
  • Gary J
    , contributor
    Comments (5580) | Send Message
     
    Ya think?
    20 Apr 2013, 06:45 AM Reply Like
  • justaminute
    , contributor
    Comments (804) | Send Message
     
    CNBC was pretty good about 20 years ago.
    19 Apr 2013, 11:30 PM Reply Like
  • thibaud
    , contributor
    Comments (165) | Send Message
     
    If the surgeons aren't trained properly, they won't know how to use the device safely. Not much evidence that ISRG gives a damn about training. Short ISRG.
    20 Apr 2013, 12:05 AM Reply Like
  • Gary J
    , contributor
    Comments (5580) | Send Message
     
    Very strange since training is a major source of income for them. What backup sources do you have for this statement?
    20 Apr 2013, 06:48 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4100) | Send Message
     
    Compared to the number of procedures I do not feel that there are many problems. There can always go something wrong in operations whether robo assisted or traditional.
    20 Apr 2013, 07:02 AM Reply Like
  • 5967241
    , contributor
    Comments (89) | Send Message
     
    Very scary, time to take profits http://tinyurl.com/c9r...
    20 Apr 2013, 09:16 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4100) | Send Message
     
    The question is NOT whether things can go wrong. The question is how often when you compare procedures. You could probably come up with a big number of patients after regular surgery with complications including death.

     

    I have no position in ISRG but I am following this discussion intensely. The internet seems to lead to exaggeration in general and short positions use this in an efficient manner. Social hype volatility, a new phenomenon in the stock market.
    20 Apr 2013, 09:37 AM Reply Like
  • Moon Kil Woong
    , contributor
    Comments (11474) | Send Message
     
    ISRG condones and supports experimental surgeries on patients that are not approved by the FDA such as heart surgery, etc. It is inevitable that they will be pulled into losing cases related to these as long as they support this to eventually get coronary and other surgeries approved.
    20 Apr 2013, 01:29 PM Reply Like
  • Gary J
    , contributor
    Comments (5580) | Send Message
     
    proof?
    20 Apr 2013, 01:42 PM Reply Like
  • TruffelPig
    , contributor
    Comments (4100) | Send Message
     
    Really. I like proof too. Obviously outside of the US FDA is irrelevant and the local authorities and regulations are relevant.
    20 Apr 2013, 06:18 PM Reply Like
  • tombo
    , contributor
    Comments (316) | Send Message
     
    This is actually standard operating procedure. How else are you supposed to show that a new procedure is safe and effective? The FDA won't approve a new indication unless you have evidence to back it up. Someone's got to be the first one to try a new device / drug / procedure, or else we'd still be bleeding patients with leeches to cure them.
    22 Apr 2013, 11:59 AM Reply Like
  • Gary J
    , contributor
    Comments (5580) | Send Message
     
    It's called oversight.
    22 Apr 2013, 12:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs